Multivessel Disease (MVD): 60 Second Insights
Published: 08 March 2018
57sPart 1 | Session 1 Keith Oldroyd Keith G Oldroyd
1m 7sPart 1 | Session 2 Simon Walsh Simon J Walsh
1m 8sPart 1 | Session 3 Paul Knaapen Paul Knaapen
53sPart 1 | Session 4 Colin Berry Colin Berry
51sPart 2 | Session 1 Keith Oldroyd Keith G Oldroyd
57sPart 2 | Session 2 Simon Walsh Simon J Walsh
1m 15sPart 2 | Session 3 Paul Knaapen Paul Knaapen
1m 10sPart 2 | Session 4 Colin Berry Colin Berry
A short series of 60-second insight videos on Multivessel Disease (MVD).
More from this programme
How do manage patients with multi-vessel disease during PPCI?
Do you think we should be doing multi-vessel revascularisation instead of CABG? If so, in which cases?
Do you prefer Clopidogrel, Ticagrelor or Prasugrel?
Do you have any concerns giving adenosine during PPCI or would your prefer and adenosine-free technique?
Do you believe registry (i.e. culprit only) or RCT data (treat all vessels)?
Do you believe coronary physiology has a role in non-culprit PPCI decision-making?
Are you using G2B3A inhibitors like ReoPro?
Are you using Bivalirudin or Heparin?
What trials best support the use of MVD PCI?
Should we balloon acutely and then returning to stent the following morning?
Keith G Oldroyd
Clinical Director of Cardiology
Professor Keith G Oldroyd MBChB; MD(Hons); FRCP(Glasg); FSCAI is a Consultant Interventional Cardiologist at the West of Scotland Regional Heart and Lung Centre in the Golden Jubilee National Hospital. He holds a personal chair within the Institute of Cardiovascular and Medical Sciences, University of Glasgow. He qualified in medicine from the University of Aberdeen in 1982.
In 2007 he became the first Clinical Director of Cardiology at the newly created West of Scotland Regional Heart and Lung Centre. From 2011-2014 he was also Director of R&D and currently he leads on CV research for NHS Scotland. His own research interests include the clinical and experimental assessment of novel drug eluting stents and the use of invasive physiological indices of stenosis severity to guide decision making in the cath lab. He has been a principal investigator in several international trials including FAME, FAME 2, PRAMI and LEADERS FREE, all of which have been published in…